Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biohaven Pharmaceuticals
Biotech
Biohaven fails phase 3 SMA test but plans talks with FDA
The biotech plans to talk to the FDA about the next steps in SMA and is stepping up its interest in obesity on the strength of the data.
Nick Paul Taylor
Nov 25, 2024 9:56am
Biohaven bounces back with phase 3 ultra-rare disease win
Sep 23, 2024 9:22am
Immunovant promotes next-gen FcRn drug in race to rival Vyvgart
May 30, 2024 7:02am
Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
Jan 26, 2024 9:30am
A blow for Biohaven as FDA refuses failed rare disease drug
Jul 27, 2023 9:41am
Biohaven turns to licensing once again to bolster neuro pipeline
Mar 22, 2023 11:00am
